BRL Medicine
Latest round
- Series B
Last raised
- Nov 2024
Total raised
- $56M
Investors
- 6
About BRL Medicine
Based in Shanghai, China, and founded in 2013, BRL Medicine operates as a biotechnology company that focuses on providing gene editing, cell therapy, and related services. The company was recognized as the National High-tech Enterprise. It has a 7000-square-meter GMP pilot plant and an operating team of nearly 200 people. The company has a branch office in Beijing. In December 2022, its gene therapy cured six cases of severe thalassemia. The founder and chairman of the board, Mingyao Liu, has served as the Dean of Life Sciences for 8 years. The company mainly provides gene therapy services. It uses gene editing and other technologies to develop therapies for the treatment of genetic diseases, malignant tumors, autoimmune diseases, etc. The company has built technology platforms including gene editing technology innovation platforms, hematopoietic stem cell platforms, non-viral fixed-point integration CAR-T platforms, etc. Products include non-viral site-specific integration of PD1-CAR-T cells targeting CD19, UCAR-T for B-cell malignant tumor diseases, etc. The company generates revenue by providing gene therapy platforms and related services. The company will advance the clinical transformation and marketing of pipeline products, as well as the global research and development of product pipelines.
Who invested in BRL Medicine
6 investors across 2 rounds
See all investors in BRL Medicine
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about BRL Medicine
Who invested in BRL Medicine?
BRL Medicine has 6 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has BRL Medicine raised?
BRL Medicine has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did BRL Medicine last raise money?
BRL Medicine's most recent round on record is a Series B, in Nov 2024.
What does BRL Medicine do?
Based in Shanghai, China, and founded in 2013, BRL Medicine operates as a biotechnology company that focuses on providing gene editing, cell therapy, and related services.
Where is BRL Medicine headquartered?
BRL Medicine is headquartered in Shanghai, China.
Which VCs invest in companies like BRL Medicine?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at BRL Medicine's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like BRL Medicine? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.